Drug Topics
APRIL 6, 2024
Joe McKamey, general manager at Marcrom’s Pharmacy in Manchester, Tennessee, talks about why pharmacies should open their own Medicare-focused insurance agency and what steps and preparations they can take to ensure a successful launch and operation.
STAT
APRIL 6, 2024
ATLANTA — Novo Nordisk’s Wegovy improved symptoms and physical function in patients who had obesity, diabetes, and a common type of heart failure, boosting Novo’s attempt to get the popular drug approved for yet another usage beyond weight loss. The study, being presented here on Saturday at the American College of Cardiology conference and published in the New England Journal of Medicine , reports results from the second large trial Novo has conducted on Wegovy in heart fai
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
APRIL 6, 2024
At AAP 2024, Kathy Campbell, PharmD, discussed obstacles that pharmacies may face when transitioning to a wellness-focused approach.
STAT
APRIL 6, 2024
STAT now publishes selected Letters to the Editor received in response to First Opinion essays to encourage robust, good-faith discussion about difficult issues. Submit a Letter to the Editor here , or find the submission form at the end of any First Opinion essay. “For national security, the U.S.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Topics
APRIL 6, 2024
Check out a recap of important pharmacy news you might’ve missed this week, dispensed in small doses.
Pharmacy Times
APRIL 6, 2024
This is the fifth indication for fam-trastuzumab deruxtecan-nxki (Enhertu; Daiichi Sankyo and AstraZeneca) approved by the FDA.
Expert insights. Personalized for you.
360 
Let's personalize your content